No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B

Hepatology

Volumn 59, Issue 2, 2014, Pages 434-442

  Kitrinos, Kathryn M ^a   Corsa, Amoreena ^a   Liu, Yang ^a   Flaherty, John ^a   Snow Lampart, Andrea ^a   Marcellin, Patrick ^b   Borroto Esoda, Katyna ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; HEPATITIS B(E) ANTIGEN; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ALLELE; ARTICLE; CELL STRAIN HEPG2; DRUG SAFETY; DRUG TOLERABILITY; GENE DOSAGE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MUTATION; OPEN STUDY; PERSISTENT INFECTION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT REFUSAL; VIREMIA;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LONGITUDINAL STUDIES; MUTATION; PATIENT COMPLIANCE; PHENOTYPE; PHOSPHOROUS ACIDS; PREVALENCE; TREATMENT OUTCOME; VIREMIA;

EID: 84893652874     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26686     Document Type: Article

References (29)

1. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009;49:S72-S84.
2. Choi MS, Yoo BC. Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver 2010;4:15-24.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2012;57:167-185.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
5. Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology 2009;49:S85-95.
6. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722.
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.
8. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-758.
9. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
10. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
11. Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006;50:2471-2477.
12. Curtis M, Hinkle J, Harris J, Borroto-Esoda K, Zhu Y. Tenofovir is equally active in vitro against wild-type HBV clinical isolates of genotypes A-H. Poster 955. In: 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31 to November 4; San Francisco, CA; 2008.
13. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10:625-633.
14. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
15. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during tenofovir disoproxil fumarate treatment for chronic hepatitis. Lancet 2013;381:468-475.
16. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-773.
17. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
18. Zhu Y, Curtis M, Borroto-Esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays. J Virol Methods 2011;173:340-346.
19. Yang H, Westland C, Xiong S, Delaney WE 4th. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res 2004;61:27-36.
20. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997;41:1715-1720.
21. Svarovskaia ES, Curtis M, Zhu Y, Borroto-Esoda K, Miller MD, Berg T, et al. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. J Viral Hepat 2013;20:131-140.
22. Marcellin T, Buti M, Gane E, Tsai N, Sievert W, Jacobson I, et al. Six years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Poster 1423799. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases; November 9-13; Boston, MA; 2012.
23. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011;53:1854-1863.
24. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013;58:505-513.
25. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443-451.
26. Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, et al. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. J Viral Hepat 2011;18:e475-481.
27. Levrero M, Cimino L, Lampertico P, Viganò M, Gaeta GB, Brancaccio G, et al. Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment: results of the OptiB Italian Multicenter Prospective Open Label Study. In: Annual Meeting of the American Association for the Study of Liver Diseases; October 29 to November 2; Boston, MA; 2010.
28. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247-254.
29. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.